Trial of Artificial Intelligence for Chest Radiography

Artificial Intelligence for Chest Radiography: Impact on Economics, Patient Outcomes and Radiology Service Delivery

NCT06456203•Duke-NUS Graduate Medical School

Summary

Randomized Clinical Trial of the impact of Chest radiograph AI-assisted triage and report generation upon clinical outcomes and an economic analysis of impact of AI decision support on radiology service delivery.

Detailed Description

Randomized, prospective selection of patients. Control group involves radiologists reporting chest radiographs as per reference standard clinical workflow Intervention group involves radiologists assisted with AI reporting an AI-triaged worklist of chest radiographs using an AI report generation tool Clinical outcomes on patients are studied at pre-determined study endpoints, including time to discharge from the hospital and re-admission rates. Economic analysis on cost-avoidance from man-hours saved from report generation and triage.

Eligibility

Age

14 - 130 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•All patients attending radiography to have chest radiographs during the study period

Exclusion Criteria

•age below 14
•deceased before discharge
•chest radiograph performed in non-standard projections

Key Dates

Start Date

October 1, 2024

Primary Completion Date

September 1, 2025

Completion Date

December 1, 2025

Last Updated

June 13, 2024

Enrollment

10,000

ESTIMATED participants

Conditions

PneumoniaLung Cancer

Interventions

DIAGNOSTIC_TEST

Magnetic Resonance Imaging of the Lung: Oncological Applications

NCT07486219

Lung Cancer (NSCLC)

View study

RECRUITING

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

NCT07485114

Renal Cell Carcinoma (Kidney Cancer)Non Small Cell Lung Cancer+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 13, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Trial of Artificial Intelligence for Chest Radiography

Inclusion Criteria

Exclusion Criteria

Magnetic Resonance Imaging of the Lung: Oncological Applications

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer